Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of cancer treatment1-3.Inadequately controlled emesis significantly impairs quality of life1. e-MANAgE is a tool in the form of an App to guide physician in evaluating the emetogenecity level of chemotherapy (single/ combination) administered to their patients and in turn better management of CINV The concept of the e-MANAgE is to provide a reliable method of predicting the risk of emesis following cancer chemotherapy. This App is developed by MSD Pharmaceuticals Pvt. Ltd., India.
Copyright © 2015 MSD Pharmaceuticals Pvt. Ltd., a subsidiary of Merck Sharp & Dohme Corp., Whitehouse Station, N.J., U.S.A. All rights reserved. ONCO-1142625-0000 25/02/2015 24/02/2016
Reference: 1) Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4(3):191-6. 2) Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-8. 3) Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7(2):189-95. less
|